Kolexia
Tourani Jean-Marc Oncologie médicale
Tourani Jean-Marc
Oncologie médicale
Hôpital La Miletrie
Poitiers, France
113 Activités
8 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome épidermoïde Métastase tumorale Carcinome pulmonaire à petites cellules Carcinome pulmonaire non à petites cellules Tumeurs du poumon Tumeurs colorectales Néphrocarcinome Tumeurs de la tête et du cou

Collaborateurs

Voir plus
Bouchaert Patrick
Bouchaert Patrick
Hôpital La Miletrie, Poitiers, France
Oudard Stephane
Oudard Stephane
Hôpital Européen Georges Pompidou, Paris, France
Joncour Anthony
Joncour Anthony
Hôpital La Miletrie, Poitiers, France
Tougeron David
Tougeron David
Hôpital La Miletrie, Poitiers, France

Industries

Voir plus
MSD
4 collaboration(s)
Dernière en 2023
A+A
2 collaboration(s)
Dernière en 2020
Servier
1 collaboration(s)
Dernière en 2020
GSK
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
European journal of cancer (Oxford, England : 1990)   09 novembre 2022
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology   28 octobre 2022
670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis)
Abstract Book of the ESMO Congress 2021, 16 – 21 September 2021   01 septembre 2021
BIBW2992ORL: A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy of Afatinib (BIBW2992) in Maintenance Therapy After Post- Operative Radio-chemotherapy in Squamous-cell Carcinoma of the Head and Neck: GORTEC 2010-02
Essai Clinique (Boehringer Ingelheim)   28 mai 2021
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
European journal of cancer (Oxford, England : 1990)   27 novembre 2020
732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
LBA38 Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 “PembroRad” randomized trial
Abstract Book of the ESMO Virtual Congress2020 19 – 21 September / 16 – 18 October 2020   01 septembre 2020
Real-world data of cabozantinib in patients with VEGF-refractory metastatic renal cell carcinoma (mRCC): Results from the French Early Access Program (CABOREAL).
2020 Genitourinary Cancers Symposium   19 février 2020
Observational study of vaccination in cancer patients: How can vaccine coverage be improved?
Medecine et maladies infectieuses   14 décembre 2019